Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?

The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, preve...

Descripción completa

Detalles Bibliográficos
Autores principales: Dockrell, Hazel M., McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Personal View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002045/
https://www.ncbi.nlm.nih.gov/pubmed/35427852
http://dx.doi.org/10.1016/j.ebiom.2022.103993
Descripción
Sumario:The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.

Ejemplares similares